Business context and reporting period
Telomir Pharmaceuticals, Inc. reported a private placement that closed on October 5, 2026. The filing is a current report on the financing, not a quarterly or annual financial-results report.
Financing and key metrics
- The company sold 4,843,300 common shares at $1.16 per share, raising approximately $5.6 million in gross proceeds before expenses.
- The price represented a 5% discount to the applicable 10-day volume-weighted average price. Existing significant shareholder John Paul DeJoria invested an additional $1.0 million; other existing and new investors also participated.
- Placement agent Alexander Capital is entitled to a cash fee of approximately $455,000, equal to 9% of gross proceeds, plus documented expenses capped at $40,000. Net proceeds are not stated.
- The company also issued the placement agent warrants to buy 387,464 shares at $1.16 per share. The warrants are exercisable for cash and expire five years after issuance.
- The filing provides no revenue, profit, cash-flow, margin, debt, or liquidity figures, and no comparable-period financial results.
Material changes and dilution
The share sale increases the common shares outstanding, but the filing does not state the resulting share count or percentage dilution. Investors received common stock only, with no investor warrants, convertible securities, or variable-price or reset features. The placement-agent warrants create potential additional dilution if exercised.
Use of proceeds, terms and risks
Telomir intends to use proceeds primarily to support clinical development of Telomir-Zn, including its Phase 1/2 program in advanced or metastatic triple-negative breast cancer, and for working capital and general corporate purposes. The company agreed to file a resale registration statement within 30 days of closing, subject to the registration rights agreement. The shares were sold in an unregistered offering relying on Securities Act exemptions.
The filing gives no operating outlook or guidance. It does not quantify the clinical program’s funding needs or explain how long the proceeds may support operations. The financing involves common-share dilution and placement costs; the filing does not provide further assessment of these or other risks.
Investor verification points
- Check the company’s subsequent filings for the resale registration statement and its effectiveness.
- Review the purchase agreement, registration rights agreement, placement-agent warrant and engagement-letter terms referenced in the filing.
- Verify the updated shares outstanding, remaining cash after fees and expenses, and the expected allocation and duration of funding for the Telomir-Zn program.
- Monitor clinical-program updates and future filings for operating results, cash burn, liquidity and any additional financing needs.